N-boc,N'-acryloyl-4,7,10-trioxatridecane-1,13-diamine | 872679-69-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-boc,N'-acryloyl-4,7,10-trioxatridecane-1,13-diamine
• 英文别名: tert-butyl N-[3-[2-[2-[3-(prop-2-enoylamino)propoxy]ethoxy]ethoxy]propyl]carbamate
• CAS: 872679-69-1
• 化学式: C₁₈H₃₄N₂O₆
• 分子量: 374.478
• InChiKey: QTNXYJGOPIDHOT-UHFFFAOYSA-N

物化性质

• 沸点：
  534.8±50.0 °C(Predicted)
• 密度：
  1.045±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  26
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  mono-boc-4,7,10-trioxatridecane-1,13-diamine hydrochloride 、 丙烯酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以78%的产率得到N-boc,N'-acryloyl-4,7,10-trioxatridecane-1,13-diamine
  参考文献：
  名称：

  Hydrogel formulations

  摘要：

  一种聚合物前药组合物，包括一个水凝胶、一个生物活性基团和一个可逆前药连接物。前药连接物以共价键连接水凝胶和生物活性基团在一个位置，水凝胶具有多个孔，其表面有开口。孔的直径至少在至少一个开口和生物活性基团位置之间的所有点处大于生物活性基团的直径。

  公开号：

  US20060002890A1

文献信息

• Hydrogel polymeric conjugates of a prodrug
  申请人：Complex Biosystems GmbH

  公开号：EP1625856A1

  公开（公告）日：2006-02-15

  The application relates to a polymeric prodrug which comprises a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on the surface of the hydrogel. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.

  本申请涉及一种聚合物原药，它由水凝胶、生物活性分子和可逆原药连接体组成。原药连接体将水凝胶和生物活性分子共价连接在一个位置上，水凝胶表面有多个开口的孔。在至少一个开口和生物活性分子位置之间的孔隙的所有点上，孔隙的直径都大于生物活性分子的直径。
• Hydrogel
  申请人：Ascendis Pharma GmbH

  公开号：EP2594291A1

  公开（公告）日：2013-05-22

  The present invention relates to a polymeric prodrug comprising a hydrogel having cross-linkers and a non-biodegradable backbone, a biologically active moiety to be released as drug and a reversible prodrug linker, wherein the prodrug linker covalently links the hydrogel and the biologically active moiety at a position and wherein the prodrug linker is attached to the non-biodegradable backbone of the hydrogel; and the hydrogel has a plurality of pores with openings on the surface of the hydrogel, wherein the diameter of the pores is larger than the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety and wherein the cross-linkers of the hydrogel further comprise bio-degradable bonds selected from the group of chemically cleavable bonds consisting of phosphate, phosphonate, carbonate, carbamate, disulfide and ester bonds, wherein the number of crosslinks and the halflife of the bio-degradable bonds are adjusted in that almost all drug can be released before a significant amount of release of backbone can take place. The present invention also relates to respective hydrogels and methods for the manufacture of a mesoporous hydrogel-biologically active moiety conjugate.

  本发明涉及一种聚合物原药，包括具有交联剂和不可生物降解骨架的水凝胶、作为药物释放的生物活性分子和可逆原药连接体，其中原药连接体在某一位置将水凝胶和生物活性分子共价连接，原药连接体附着在水凝胶的不可生物降解骨架上；其中交联剂的数量和生物可降解键的半衰期经过调整，几乎所有药物都可以在骨架大量释放之前释放。 本发明还涉及相应的水凝胶和制造介孔水凝胶-生物活性分子共轭物的方法。
• Solid support
  申请人：LIFE TECHNOLOGIES AS

  公开号：US11041068B2

  公开（公告）日：2021-06-22

  This invention relates to polymer particles for solid phase oligonucleotide synthesis. The oligonucleotide may be linked to the particle via a linker having an amide-oligoethyleneglycol-amine structure. The particles may be considered to act as a solid support during the oligonucleotide synthesis. Also disclosed are processes for preparing such polymer particles, compositions and systems comprising such particles, and uses thereof.

  本发明涉及用于固相寡核苷酸合成的聚合物颗粒。寡核苷酸可通过具有酰胺-醇聚乙二醇-胺结构的连接剂与颗粒连接。在寡核苷酸合成过程中，颗粒可被视为固体支持物。此外，还公开了制备这种聚合物微粒的工艺、包含这种微粒的组合物和系统及其用途。
• Compact Biocompatible Quantum Dots via RAFT-Mediated Synthesis of Imidazole-Based Random Copolymer Ligand
  作者：Wenhao Liu、Andrew B. Greytak、Jungmin Lee、Cliff R. Wong、Jongnam Park、Lisa F. Marshall、Wen Jiang、Peter N. Curtin、Alice Y. Ting、Daniel G. Nocera、Dai Fukumura、Rakesh K. Jain、Moungi G. Bawendi

  DOI：10.1021/ja908137d

  日期：2010.1.20

  We present a new class of polymeric ligands for quantum dot (OD) water solubilization to yield biocompatible and derivatizable QDs with compact size (similar to 10-12 nm diameter), high quantum yields (>50%), excellent stability across a large pH range (pH 5-10.5), and low nonspecific binding. To address the fundamental problem of thiol instability in traditional ligand exchange systems, the polymers here employ a stable multidentate imidazole binding motif to the OD surface. The polymers are synthesized via reversible addition-fragmentation chain transfer-mediated polymerization to produce molecular weight controlled monodisperse random copolymers from three types of monomers that feature imidazole groups for CID binding, polyethylene glycol (PEG) groups for water solubilization, and either primary amines or biotin groups for derivatization. The polymer architecture can be tuned by the monomer ratios to yield aqueous QDs with targeted surface functionalities. By incorporating amino-PEG monomers, we demonstrate covalent conjugation of a dye to form a highly efficient QD-dye energy transfer pair as well as covalent conjugation to streptavidin for high-affinity single molecule imaging of biotinylated receptors on live cells with minimal nonspecific binding. The small size and low serum binding of these polymer-coated QDs also allow us to demonstrate their utility for in vivo imaging of the tumor microenvironment in live mice.
• HYDROGEL CONJUGATES
  申请人：Ascendis Pharma GmbH

  公开号：EP1781335B1

  公开（公告）日：2021-01-13